共 50 条
Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis
被引:0
|作者:
Montalban, X.
[1
]
Hemmer, B.
[2
]
Rammohan, K.
[3
]
Giovannoni, G.
[4
]
de Seze, J.
[5
]
Bar-Or, A.
[6
]
Arnold, D.
[6
]
Sauter, A.
[7
]
Leppert, D.
[8
]
Chin, P.
[9
]
Garren, H.
[8
]
Messier, M.
[8
]
Wolinski, J.
[10
]
Kakarieka, A.
[8
]
Masterman, D.
[9
]
机构:
[1] Vall dHebron Univ Hosp, Dept Neurol Neuroimmunol, Barcelona, Spain
[2] Tech Univ Munich, Neurol, D-80290 Munich, Germany
[3] Univ Miami Hlth Syst, MS Ctr Excellence, Miami, FL USA
[4] Barts & London Queen Marys Sch Med & Dent, Neurosci, London, England
[5] Univ Hosp Strasbourg, Neurol, Strasbourg, France
[6] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada
[7] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[8] F Hoffmann La Roche & Co Ltd, Neurosci, CH-4002 Basel, Switzerland
[9] Genentech Roche, Neurosci, San Francisco, CA USA
[10] Univ Texas Houston, Sch Med, Neurosci, Houston, TX USA
关键词:
D O I:
暂无
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
F3049
引用
收藏
页码:706 / 706
页数:1
相关论文